Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Non-Current Debt (2016 - 2019)

Historic Non-Current Debt for NovaBay Pharmaceuticals (NBY) over the last 4 years, with Q2 2019 value amounting to $1.1 million.

  • NovaBay Pharmaceuticals' Non-Current Debt changed N/A to $1.1 million in Q2 2019 from the same period last year, while for Jun 2019 it was $1.1 million, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2015, which is N/A changed from last year.
  • According to the latest figures from Q2 2019, NovaBay Pharmaceuticals' Non-Current Debt is $1.1 million.
  • Over the past 5 years, NovaBay Pharmaceuticals' Non-Current Debt peaked at $3.1 million during Q1 2016, and registered a low of $524000.0 during Q2 2016.
  • Moreover, its 3-year median value for Non-Current Debt was $1.4 million (2015), whereas its average is $1.6 million.